BC
SWTX

Birchview Capital’s SpringWorks Therapeutics SWTX Stock Holding History

Birchview Capital’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-8,280
Closed -$365K – 78
2025
Q1 		$365K Sell
8,280
-1,720
-17% -$79.2K 0.32% 38
2024
Q4 		$361K Hold
10,000
– – 0.29% 42
2024
Q3 		$320K Hold
10,000
– – 0.28% 43
2024
Q2 		$377K Hold
10,000
– – 0.35% 39
2024
Q1 		$492K Hold
10,000
– – 0.4% 35
2023
Q4 		$365K Buy
+10,000
New +$261K 0.29% 41

Other funds holding SWTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Birchview Capital's SWTX Position: Q2 2025 in Review

Birchview Capital sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 8,280 shares — an estimated $365K sold.

Birchview Capital first reported a position in SWTX in Q4 2023 and held it in 6 quarters. The position peaked at $492K in Q1 2024. 223 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

  • Birchview Capital reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Birchview Capital sold 8,280 SpringWorks Therapeutics shares in Q2 2025, an estimated $365K.
  • Birchview Capital first reported a position in SpringWorks Therapeutics in Q4 2023 and held it in 6 quarters.
  • Birchview Capital's SpringWorks Therapeutics position peaked at $492K in Q1 2024.
  • 223 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on Birchview Capital's 13F filing for Q2 2025, filed 14 Aug 2025.